Home > Research > Publications & Outputs > Breakthrough SARS-CoV-2 infections in double an...

Associated organisational unit

Links

Text available via DOI:

View graph of relations

Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England : REACT-1 study. / Chadeau-Hyam, M.; Eales, O.; Bodinier, B. et al.

In: eClinicalMedicine, Vol. 48, 101419, 30.06.2022.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Chadeau-Hyam, M, Eales, O, Bodinier, B, Wang, H, Haw, D, Whitaker, M, Elliott, J, Walters, CE, Jonnerby, J, Atchison, C, Diggle, PJ, Page, AJ, Ashby, D, Barclay, W, Taylor, G, Cooke, G, Ward, H, Darzi, A, Donnelly, CA & Elliott, P 2022, 'Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study', eClinicalMedicine, vol. 48, 101419. https://doi.org/10.1016/j.eclinm.2022.101419

APA

Chadeau-Hyam, M., Eales, O., Bodinier, B., Wang, H., Haw, D., Whitaker, M., Elliott, J., Walters, C. E., Jonnerby, J., Atchison, C., Diggle, P. J., Page, A. J., Ashby, D., Barclay, W., Taylor, G., Cooke, G., Ward, H., Darzi, A., Donnelly, C. A., & Elliott, P. (2022). Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. eClinicalMedicine, 48, [101419]. https://doi.org/10.1016/j.eclinm.2022.101419

Vancouver

Chadeau-Hyam M, Eales O, Bodinier B, Wang H, Haw D, Whitaker M et al. Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. eClinicalMedicine. 2022 Jun 30;48:101419. Epub 2022 May 6. doi: 10.1016/j.eclinm.2022.101419

Author

Bibtex

@article{55c5f6aceb454adbb834594d90a7bfb5,
title = "Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study",
abstract = "Background: Prevalence of SARS-CoV-2 infection with Delta variant was increasing in England in late summer 2021 among children aged 5 to 17 years, and adults who had received two vaccine doses. In September 2021, a third (booster) dose was offered to vaccinated adults aged 50 years and over, vulnerable adults and healthcare/care-home workers, and a single vaccine dose already offered to 16 and 17 year-olds was extended to children aged 12 to 15 years. Methods: SARS-CoV-2 community prevalence in England was available from self-administered throat and nose swabs using reverse transcriptase polymerase chain reaction (RT-PCR) in round 13 (24 June to 12 July 2021, N = 98,233), round 14 (9 to 27 September 2021, N = 100,527) and round 15 (19 October to 5 November 2021, N = 100,112) from the REACT-1 study randomised community surveys. Linking to National Health Service (NHS) vaccination data for consenting participants, we estimated vaccine effectiveness in children aged 12 to 17 years and compared swab-positivity rates in adults who received a third dose with those who received two doses. Findings: Weighted SARS-CoV-2 prevalence was 1.57% (1.48%, 1.66%) in round 15 compared with 0.83% (0.76%, 0.89%) in round 14, and the previously observed link between infections and hospitalisations and deaths had weakened. Vaccine effectiveness against infection in children aged 12 to 17 years was estimated (round 15) at 64.0% (50.9%, 70.6%) and 67.7% (53.8%, 77.5%) for symptomatic infections. Adults who received a third vaccine dose were less likely to test positive compared to those who received two doses, with adjusted OR of 0.36 (0.25, 0.53). Interpretation: Vaccination of children aged 12 to 17 years and third (booster) doses in adults were effective at reducing infection risk. High rates of vaccination, including booster doses, are a key part of the strategy to reduce infection rates in the community. ",
keywords = "Booster dose, Children vaccination, SARS-CoV-2 prevalence, School-aged children, Vaccine effectiveness",
author = "M. Chadeau-Hyam and O. Eales and B. Bodinier and H. Wang and D. Haw and M. Whitaker and J. Elliott and C.E. Walters and J. Jonnerby and C. Atchison and P.J. Diggle and A.J. Page and D. Ashby and W. Barclay and G. Taylor and G. Cooke and H. Ward and A. Darzi and C.A. Donnelly and P. Elliott",
year = "2022",
month = jun,
day = "30",
doi = "10.1016/j.eclinm.2022.101419",
language = "English",
volume = "48",
journal = "eClinicalMedicine",

}

RIS

TY - JOUR

T1 - Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England

T2 - REACT-1 study

AU - Chadeau-Hyam, M.

AU - Eales, O.

AU - Bodinier, B.

AU - Wang, H.

AU - Haw, D.

AU - Whitaker, M.

AU - Elliott, J.

AU - Walters, C.E.

AU - Jonnerby, J.

AU - Atchison, C.

AU - Diggle, P.J.

AU - Page, A.J.

AU - Ashby, D.

AU - Barclay, W.

AU - Taylor, G.

AU - Cooke, G.

AU - Ward, H.

AU - Darzi, A.

AU - Donnelly, C.A.

AU - Elliott, P.

PY - 2022/6/30

Y1 - 2022/6/30

N2 - Background: Prevalence of SARS-CoV-2 infection with Delta variant was increasing in England in late summer 2021 among children aged 5 to 17 years, and adults who had received two vaccine doses. In September 2021, a third (booster) dose was offered to vaccinated adults aged 50 years and over, vulnerable adults and healthcare/care-home workers, and a single vaccine dose already offered to 16 and 17 year-olds was extended to children aged 12 to 15 years. Methods: SARS-CoV-2 community prevalence in England was available from self-administered throat and nose swabs using reverse transcriptase polymerase chain reaction (RT-PCR) in round 13 (24 June to 12 July 2021, N = 98,233), round 14 (9 to 27 September 2021, N = 100,527) and round 15 (19 October to 5 November 2021, N = 100,112) from the REACT-1 study randomised community surveys. Linking to National Health Service (NHS) vaccination data for consenting participants, we estimated vaccine effectiveness in children aged 12 to 17 years and compared swab-positivity rates in adults who received a third dose with those who received two doses. Findings: Weighted SARS-CoV-2 prevalence was 1.57% (1.48%, 1.66%) in round 15 compared with 0.83% (0.76%, 0.89%) in round 14, and the previously observed link between infections and hospitalisations and deaths had weakened. Vaccine effectiveness against infection in children aged 12 to 17 years was estimated (round 15) at 64.0% (50.9%, 70.6%) and 67.7% (53.8%, 77.5%) for symptomatic infections. Adults who received a third vaccine dose were less likely to test positive compared to those who received two doses, with adjusted OR of 0.36 (0.25, 0.53). Interpretation: Vaccination of children aged 12 to 17 years and third (booster) doses in adults were effective at reducing infection risk. High rates of vaccination, including booster doses, are a key part of the strategy to reduce infection rates in the community.

AB - Background: Prevalence of SARS-CoV-2 infection with Delta variant was increasing in England in late summer 2021 among children aged 5 to 17 years, and adults who had received two vaccine doses. In September 2021, a third (booster) dose was offered to vaccinated adults aged 50 years and over, vulnerable adults and healthcare/care-home workers, and a single vaccine dose already offered to 16 and 17 year-olds was extended to children aged 12 to 15 years. Methods: SARS-CoV-2 community prevalence in England was available from self-administered throat and nose swabs using reverse transcriptase polymerase chain reaction (RT-PCR) in round 13 (24 June to 12 July 2021, N = 98,233), round 14 (9 to 27 September 2021, N = 100,527) and round 15 (19 October to 5 November 2021, N = 100,112) from the REACT-1 study randomised community surveys. Linking to National Health Service (NHS) vaccination data for consenting participants, we estimated vaccine effectiveness in children aged 12 to 17 years and compared swab-positivity rates in adults who received a third dose with those who received two doses. Findings: Weighted SARS-CoV-2 prevalence was 1.57% (1.48%, 1.66%) in round 15 compared with 0.83% (0.76%, 0.89%) in round 14, and the previously observed link between infections and hospitalisations and deaths had weakened. Vaccine effectiveness against infection in children aged 12 to 17 years was estimated (round 15) at 64.0% (50.9%, 70.6%) and 67.7% (53.8%, 77.5%) for symptomatic infections. Adults who received a third vaccine dose were less likely to test positive compared to those who received two doses, with adjusted OR of 0.36 (0.25, 0.53). Interpretation: Vaccination of children aged 12 to 17 years and third (booster) doses in adults were effective at reducing infection risk. High rates of vaccination, including booster doses, are a key part of the strategy to reduce infection rates in the community.

KW - Booster dose

KW - Children vaccination

KW - SARS-CoV-2 prevalence

KW - School-aged children

KW - Vaccine effectiveness

U2 - 10.1016/j.eclinm.2022.101419

DO - 10.1016/j.eclinm.2022.101419

M3 - Journal article

VL - 48

JO - eClinicalMedicine

JF - eClinicalMedicine

M1 - 101419

ER -